Galectin-1 Inhibits Hepatic Autophagy via FIP200, Exacerbating Steatosis: Evidence and Implications

Study Background and Research Question

Non-alcoholic fatty liver disease (NAFLD) constitutes the most prevalent chronic liver disorder worldwide, encompassing a spectrum from benign hepatic steatosis to progressive non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Central to NAFLD development is insulin resistance and defective hepatic autophagy, yet the upstream molecular mechanisms governing these processes remain incompletely defined. Recent clinical and preclinical studies have implicated galectin-1 (Gal-1), a β-galactoside-binding lectin, in metabolic dysfunction, insulin resistance, and fibrotic progression, but its direct mechanistic contributions to NAFLD have not been fully elucidated.

The reference study (Zheng et al., 2026) addresses the critical question: How does Gal-1 modulate hepatic autophagy and metabolic homeostasis, and what are the molecular underpinnings linking Gal-1 to NAFLD progression?

Key Innovation from the Reference Study

The central innovation lies in the identification of a direct protein–protein interaction between Gal-1 and the autophagy scaffold protein FIP200, revealing a new regulatory axis in hepatic metabolism. The study demonstrates that Gal-1 overexpression alone is sufficient to induce hallmarks of NAFLD—hepatic steatosis, dyslipidemia, and insulin resistance—even in the absence of dietary or metabolic stressors. Mechanistically, Gal-1 binds FIP200, disrupting the assembly of the ULK1 autophagy initiation complex, thereby impairing autophagic flux and exacerbating lipid accumulation in hepatocytes. Structural mapping localized the interaction interface to Gal-1 residues TYR120/PHE134 and the FIP200 claw domain, with a functional binding affinity (Kd = 113.1 μM). Point mutations disrupting this interface abolish Gal-1-mediated autophagy inhibition and metabolic dysregulation, directly establishing causality.

Methods and Experimental Design Insights

The research team combined in vivo transgenic mouse models, cellular assays, and proteomic profiling to dissect the Gal-1–FIP200 axis:

• Transgenic overexpression and knockout models: Mouse models with hepatocyte-specific Gal-1 overexpression were compared to Gal-1-knockout counterparts, enabling the assessment of Gal-1’s sufficiency and necessity in NAFLD phenotypes.
• Autophagic flux monitoring: Quantitative western blotting for p62 and LC3-II conversion was used to assess autophagic degradation activity under varying Gal-1 expression levels.
• Proteomics and co-immunoprecipitation: Comprehensive proteomic screens identified FIP200 as a Gal-1 binding partner, confirmed by co-IP and pull-down assays.
• Structural mapping: Peptide mapping and site-directed mutagenesis pinpointed the interaction interface between Gal-1 and FIP200, linking structural determinants to functional outcomes.
• Metabolic phenotyping: Glucose and insulin tolerance tests, together with lipid profiling, established the impact of Gal-1 manipulation on systemic metabolic homeostasis.

Core Findings and Why They Matter

The reference study demonstrates that hepatic overexpression of Gal-1 triggers steatosis, insulin resistance, and dyslipidemia, even in the absence of exogenous metabolic stress. Proteomic and biochemical analyses reveal that Gal-1 drives a profound blockade of autophagic flux, as indicated by p62 accumulation and reduced LC3-II conversion. Mechanistically, Gal-1 binds directly to the claw domain of FIP200, disrupting the assembly of the ULK1 complex, a pivotal initiator of autophagy. This protein–protein interaction, with a measured Kd of 113.1 μM, is essential for Gal-1’s inhibitory role: point mutations that disrupt Gal-1–FIP200 binding also abolish autophagy suppression and the downstream metabolic phenotype.

Notably, Gal-1 also suppresses FIP200 expression at both transcriptional and post-translational levels, indicating a dual-layered inhibition of the autophagy machinery. Collectively, these findings define the Gal-1–FIP200 axis as a novel and actionable node integrating metabolic stress, autophagy dysfunction, and NAFLD pathogenesis.

Comparison with Existing Internal Articles and the Broader Context

Recent advances in NAFLD and fibrosis research have highlighted the centrality of oxidative stress, ASK1 signaling, and autophagy in disease progression. Articles such as "Selonsertib (GS-4997): ASK1 Inhibition in Fibrosis & NAFLD Models" and "Selonsertib (GS-4997): Advancing NAFLD & Fibrosis Research" emphasize the utility of ASK1 inhibitors in dissecting the crosstalk between inflammation, oxidative stress, and autophagy. While these resources focus on ASK1 inhibition as a strategy to modulate oxidative stress pathways and fibrosis, the present study extends the mechanistic landscape by implicating Gal-1–mediated autophagy impairment as a parallel and potentially synergistic driver of metabolic liver injury.

Notably, workflows leveraging selective ASK1 inhibitors like Selonsertib (GS-4997) have been shown to clarify the roles of stress kinases in both autophagy regulation and fibrotic responses. Integration of Gal-1–FIP200 axis studies with ASK1 pathway interrogation offers an expanded toolkit for metabolic disease research, as discussed in the aforementioned internal articles.

Limitations and Transferability

While the study provides compelling evidence for the pathophysiological role of Gal-1–FIP200 disruption in NAFLD, several limitations merit consideration. First, the binding affinity (Kd = 113.1 μM) of the Gal-1–FIP200 interaction, though functionally relevant in the experimental context, may differ in human pathophysiology or under pharmacological modulation. Second, most experiments were performed in murine models or immortalized hepatocyte lines; translational validation in human primary hepatocytes and clinical samples remains essential. Third, while the study links Gal-1 to both autophagy and insulin signaling, the precise temporal and tissue-specific dynamics of these dual effects require further dissection.

Transferability of these mechanistic insights to therapeutic intervention will depend on the development of molecules or biologics capable of selectively disrupting the Gal-1–FIP200 interaction without broadly impairing physiological autophagy or immune homeostasis.

Protocol Parameters

• Gal-1 overexpression induction: For murine models, hepatic-specific overexpression was achieved using adeno-associated viral vectors; titration and timing should be optimized according to the desired disease stage modeling.
• Autophagic flux assessment: Monitor p62 and LC3-II levels by western blotting at multiple time points post-intervention to capture dynamic changes in autophagy.
• Protein–protein interaction mapping: Use site-directed mutagenesis to create Gal-1 and FIP200 mutants for functional and binding assays.
• Metabolic phenotyping: Incorporate both glucose and insulin tolerance tests, coupled with serum lipid profiling, for comprehensive assessment of metabolic impact.
• ASK1 inhibition controls: When investigating crosstalk with oxidative stress pathways, include ASK1 inhibitors such as Selonsertib (GS-4997) to delineate parallel or synergistic mechanisms (see related internal resources for detailed protocols).

Research Support Resources

This study’s mechanistic insights open new avenues for interrogating the interplay between autophagy, inflammation, and metabolic stress in NAFLD and related disorders. Researchers aiming to dissect oxidative stress and autophagy crosstalk can leverage selective ASK1 inhibitors in their workflows. For example, Selonsertib (GS-4997) (SKU B7812, APExBIO) is a potent, highly selective ASK1 ATP-competitive inhibitor suitable for research on oxidative stress signaling, inflammation, fibrosis, and diabetic kidney disease. When designing experiments to probe the Gal-1–FIP200–autophagy axis alongside ASK1 pathways, Selonsertib can be integrated as a pharmacological control or mechanistic probe—see internal guides for protocol enhancements. For compound handling and storage, consult the product information.